A well-structured resistance training program that includes compound lifts, progressive overload, and consistent weekly ...

The seven-time world champion went fastest late on at Silverstone, beating the championship leader by two tenths ahead of ...

Understanding the exponential power of compound interest is essential for navigating the modern economic landscape, building ...

Learn how CDs pay compound interest and how it affects their annual percentage yield (APY) to maximize your savings strategy ...

Jessica Rendall is a reporter with experience covering a variety of health and wellness topics, including chronic disease, infectious disease, telemedicine, mental health and health technology. Emily ...

The Food and Drug Administration on Thursday proposed excluding Novo Nordisk and Eli Lilly’s ‌weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing ...

On April 1, the U.S. Food and Drug Administration (FDA) clarified its policies on compounded drugs, including compounded versions of GLP-1 products. Compounders are permitted to produce copies of ...

A recent op-ed in the Washington Post describes the story of an author who decided he wanted to lose weight. Although he was healthy, he heard from friends how easy and effective GLP-1 medications ...

The FDA has clarified its policies regarding GLP-1s, stating that pharmacies must stop compounding GLP-1 drugs once branded versions are removed from the agency’s shortage list, signaling a narrower ...

As GLP-1 medications grow in popularity not just for treating diabetes but also for weight loss, some people are turning to alternatives that health experts warn may carry risks. Amelia Baker, a ...

Eli Lilly (LLY) has issued a public warning about potential safety risks associated with compounded tirzepatide mixed with vitamin B12. Lilly tested compounded products and found “significant levels ...

Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. as drugmakers and the FDA alike seek to crack down on the ...